{"organizations": [], "uuid": "90b1dcbb95a21e8389a3544e48ace863a38db5f8", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-evolus-announces-update-with-dwp-4/brief-evolus-announces-update-with-dwp-450-regulatory-submissions-idUSFWN1SN0O2", "country": "US", "domain_rank": 408, "title": "BRIEF-Evolus Announces Update With DWP-450 Regulatory Submissions", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-16T20:41:00.000+03:00", "replies_count": 0, "uuid": "90b1dcbb95a21e8389a3544e48ace863a38db5f8"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-evolus-announces-update-with-dwp-4/brief-evolus-announces-update-with-dwp-450-regulatory-submissions-idUSFWN1SN0O2", "ord_in_thread": 0, "title": "BRIEF-Evolus Announces Update With DWP-450 Regulatory Submissions", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "evolus inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "cmc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Evolus Inc:\n* EVOLUS ANNOUNCES PROGRESS WITH DWP-450 REGULATORY SUBMISSIONS\n* EVOLUS INC - CONFERENCE CALL SCHEDULED FOR 8:30AM ET / 5:30AM PT\n* EVOLUS INC - EVOLUS RECEIVES FDA COMPLETE RESPONSE LETTER WITH COMMENTS ISOLATED TO CMC ITEMS\n* EVOLUS INC - PLANS TO UTILIZE DAEWOONG FACILITY TO SUPPORT COMMERCIAL PRODUCTION FOLLOWING ANTICIPATED APPROVAL OF DWP-450.\n* EVOLUS INC - FDA ISSUES FAVORABLE EIR LETTER RELATED TO MANUFACTURING FACILITY\n* EVOLUS INC - DWP-450 MANUFACTURING FACILITY IS FULLY VALIDATED BY DAEWOONG UNDER CURRENT GOOD MANUFACTURING PRACTICE REQUIREMENTS\n* EVOLUS INC - IN CRL, DEFICIENCIES CITED BY FDA WERE ISOLATED TO ITEMS RELATED TO CHEMISTRY, MANUFACTURING, AND CONTROLS PROCESSES\n* EVOLUS INC - EXPECTS TO RESPOND TO FDA ABOUT CRL WITH A COMPLETE SUBMISSION TO FDA WITHIN 90 DAYS\n* EVOLUS INC - LOOK FORWARD TO WORKING CLOSELY WITH FDA AND REMAIN COMMITTED TO BRINGING DWP-450 TO MARKET BY SPRING 2019\n* EVOLUS INC - DWP-450 MANUFACTURING FACILITY HAS CAPACITY EXPECTED TO MEET ANTICIPATED PRODUCT DEMAND Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T20:41:00.000+03:00", "crawled": "2018-05-17T14:28:14.016+03:00", "highlightTitle": ""}